Belén Garijo

Chief executive of Sanofi

Appears in 1 story

Office: Chief executive officer

Born: July 31, 1960, Almansa

Education: University of Alcalá

Last updated Nov 1, 2026

Stories

Sanofi pays Regeneron $1 billion upfront to expand Dupixent alliance

Money Moves

As of October 2026: Took office May 2026; leading a strategic review of the company

Sanofi's biggest product is running out of room. Dupixent, the anti-inflammation antibody it co-developed with Regeneron, brought in $17.8 billion in 2025—roughly 36% of the French company's sales—and a key US patent expires in 2031.

Updated Oct 3